Polyunsaturated Fatty Acid Metabolism Signature in Ischemia Differs from Reperfusion in Mouse Intestine

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Gobbetti, Thomas ^a,b,c,d   Le Faouder, Pauline ^a,b,c   Bertrand, Justine ^c   Dubourdeau, Marc ^e   Barocelli, Elisabetta ^f   Cenac, Nicolas ^a,b,c   Vergnolle, Nathalie ^a,b,c  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Ambiotis SAS   (France)

^f UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

18 HYDROXYEICOSAPENTAENOATE; ICOSANOID; ICOSAPENTAENOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MU AGONIST; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN E3; PROSTAGLANDIN J2; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENTERITIS; ENZYME ACTIVITY; ENZYME KINETICS; EXPERIMENTAL MODEL; FATTY ACID METABOLISM; HISTOPATHOLOGY; INTESTINE ISCHEMIA; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; REPERFUSION INJURY; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; CYTOKINES; FATTY ACIDS, UNSATURATED; INFLAMMATION; INFLAMMATION MEDIATORS; INTESTINE, SMALL; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; PEROXIDASE; REPERFUSION INJURY; SURVIVAL RATE; TANDEM MASS SPECTROMETRY;

EID: 84884485982     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075581     Document Type: Article

References (53)

1. Buczynski MW, Dumlao DS, Dennis EA, (2009) Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res 50: 1015-1038.
2. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, et al. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21: 325-332.
3. Serhan CN, Savill J, (2005) Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 1191-1197.
4. Vollmar B, Menger MD, (2011) Intestinal ischemia/reperfusion: microcirculatory pathology and functional consequences. Langenbecks Arch Surg 396: 13-29.
5. Gobbetti T, Cenac N, Motta JP, Rolland C, Barocelli E, et al. (2011) Inflammatory proteases released in a mouse model of intestinal ischemia. Inflamm Res 60 (Supp. 1):: S295-297.
6. Otamiri T, Franzen L, Lindmark D, Tagesson C, (1987) Increased phospholipase A2 and decreased lysophospholipase activity in the small intestinal mucosa after ischaemia and revascularisation. Gut 28: 1445-1453.
7. Otamiri T, Lindahl M, Tagesson C, (1988) Phospholipase A2 inhibition prevents mucosal damage associated with small intestinal ischaemia in rats. Gut 29: 489-494.
8. Arumugam TV, Arnold N, Proctor LM, Newman M, Reid RC, et al. (2003) Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist. Br J Pharmacol 140: 71-80.
9. Cattaruzza F, Cenac N, Barocelli E, Impicciatore M, Hyun E, et al. (2006) Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents. AmJPathol 169: 177-188.
10. Gobbetti T, Cenac N, Motta JP, Rolland C, Martin L, et al. (2012) Serine protease inhibition reduces post-ischemic granulocyte recruitment in mouse intestine. Am J Pathol 180: 141-152.
11. Le Faouder P, Baillif V, Spreadbury I, Motta JP, Rousset P, et al. (2013) LC-MS/MS method for rapid and concomitant quantification of pro-inflammatory and pro-resolving polyunsaturated fatty acid metabolites. J Chromatogr B Analyt Technol Biomed Life Sci 932: 10.
12. Visioli F, Colombo C, Galli C, (1998) Oxidation of individual fatty acids yields different profiles of oxidation markers. Biochem Biophys Res Commun 245: 487-489.
13. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, et al. (2003) Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424: 434-438.
14. Sadik CD, Luster AD, (2012) Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. J Leukoc Biol 91: 207-215.
15. Lambert IH, Pedersen SF, Poulsen KA, (2006) Activation of PLA2 isoforms by cell swelling and ischaemia/hypoxia. Acta Physiol (Oxf) 187: 75-85.
16. Moore EE, Claude H. Organ Jr., (2010) memorial lecture: splanchnic hypoperfusion provokes acute lung injury via a 5-lipoxygenase-dependent mechanism. Am J Surg 200: 681-689.
17. Sapirstein A, Bonventre JV, (2000) Phospholipases A2 in ischemic and toxic brain injury. Neurochem Res 25: 745-753.
18. Koike K, Yamamoto Y, Hori Y, Ono T, (2000) Group IIA phospholipase A2 mediates lung injury in intestinal ischemia-reperfusion. Ann Surg 232: 90-97.
19. Nakamura H, Nemenoff RA, Gronich JH, Bonventre JV, (1991) Subcellular characteristics of phospholipase A2 activity in the rat kidney. Enhanced cytosolic, mitochondrial, and microsomal phospholipase A2 enzymatic activity after renal ischemia and reperfusion. J Clin Invest 87: 1810-1818.
20. Funk CD, Chen XS, Johnson EN, Zhao L, (2002) Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 68-69: 303-312.
21. Rossi A, Pergola C, Cuzzocrea S, Sautebin L, (2007) The role of 5-lipoxygenase and leukotrienes in shock and ischemia-reperfusion injury. ScientificWorldJournal 7: 56-74.
22. Fabre JE, Goulet JL, Riche E, Nguyen M, Coggins K, et al. (2002) Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J Clin Invest 109: 1373-1380.
23. Jin G, Arai K, Murata Y, Wang S, Stins MF, et al. (2008) Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke 39: 2538-2543.
24. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, et al. (2011) Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 50: 115-131.
25. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP, (2006) Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J Appl Physiol 100: 233-239.
26. Domoki F, Veltkamp R, Thrikawala N, Robins G, Bari F, et al. (1999) Ischemia-reperfusion rapidly increases COX-2 expression in piglet cerebral arteries. Am J Physiol 277: H1207-1214.
27. Camacho M, Rodriguez C, Guadall A, Alcolea S, Orriols M, et al. (2011) Hypoxia upregulates PGI-synthase and increases PGI release in human vascular cells exposed to inflammatory stimuli. J Lipid Res 52: 720-731.
28. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, et al. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5: 698-701.
29. Ajuebor MN, Singh A, Wallace JL, (2000) Cyclooxygenase-2-derived prostaglandin D(2) is an early anti- inflammatory signal in experimental colitis [In Process Citation]. AmJPhysiol GastrointestLiver Physiol 279: G238-G244.
30. Fiorucci S, de Lima OM Jr, Mencarelli A, Palazzetti B, Distrutti E, et al. (2002) Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123: 1598-1606.
31. Boros M, Bako L, Nagy S, (1991) Effect of antioxidant therapy on cyclooxygenase-derived eicosanoid release during intestinal ischemia-reperfusion. Eur Surg Res 23: 141-150.
32. Turnage RH, Kadesky KM, Bartula L, Guice KS, Oldham KT, et al. (1995) Splanchnic PGI2 release and "no reflow" following intestinal reperfusion. J Surg Res 58: 558-564.
33. Kawata K, Takeyoshi I, Iwanami K, Sunose Y, Tsutsumi H, et al. (2003) The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury. Hepatogastroenterology 50: 1970-1974.
34. Zeiger SL, Musiek ES, Zanoni G, Vidari G, Morrow JD, et al. (2009) Neurotoxic lipid peroxidation species formed by ischemic stroke increase injury. Free Radic Biol Med 47: 1422-1431.
35. Abdelrahman M, Sivarajah A, Thiemermann C, (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65: 772-781.
36. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, et al. (2001) Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120: 460-469.
37. Scher JU, Pillinger MH, (2005) 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 114: 100-109.
38. Morisseau C, Hammock BD, (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45: 311-333.
39. Zeldin DC KJ, Falck JR, Winder BS, Hammock BD, Snapper JR, et al. (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 268: 5.
40. Batchu SN, Chaudhary KR, El-Sikhry H, Yang W, Light PE, et al. (2012) Role of PI3Kalpha and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection. J Mol Cell Cardiol 53: 43-52.
41. Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102: 16747-16752.
42. D'Aldebert E, Cenac N, Rousset P, Martin L, Rolland C, et al. (2011) Transient receptor potential vanilloid 4 activated inflammatory signals by intestinal epithelial cells and colitis in mice. Gastroenterology 140: 275-285.
43. Cenac N, Altier C, Zamponi GW, Vergnolle N, (2008) Histamine and serotonin sensitizes the transient receptor potential vanilloid receptor 4 to induce visceral allodynia and hyperalgesia. Gastroenterology 134: A559-A560.
44. Cenac N, Altier C, Motta JP, d'Aldebert E, Galeano S, et al. (2010) Potentiation of TRPV4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity. Gut 59: 481-488.
45. Vergnolle N, Cenac N, Altier C, Cellars L, Chapman K, et al. (2010) A role for transient receptor potential vanilloid 4 in tonicity-induced neurogenic inflammation. Br J Pharmacol 159: 1161-1173.
46. Denadai-Souza A, Martin L, de Paula MA, de Avellar MC, Muscara MN, et al. (2012) Role of transient receptor potential vanilloid 4 in rat joint inflammation. Arthritis Rheum 64: 1848-1858.
47. Chatter R, Cenac N, Roussis V, Kharrat R, Vergnolle N, (2012) Inhibition of sensory afferents activation and visceral pain by a brominated algal diterpene. Neurogastroenterol Motil 24: e336-343.
48. Andersson U, Tracey KJ, (2012) Neural reflexes in inflammation and immunity. J Exp Med 209: 1057-1068.
49. Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, et al. (2013) A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 122: 608-617.
50. Serhan CN, Yacoubian S, Yang R, (2008) Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 3: 279-312.
51. Duffield JS, Hong S, Vaidya VS, Lu Y, Fredman G, et al. (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 177: 5902-5911.
52. Keyes KT, Ye Y, Lin Y, Zhang C, Perez-Polo JR, et al. (2010) Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol 299: H153-164.
53. Serhan CN, (2007) Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.